Hot Features
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for ... AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.01 | 1.38888888889 | 0.72 | 0.750101 | 0.7001 | 18989 | 0.72270729 | CS |
| 4 | 0.0079 | 1.0940312976 | 0.7221 | 0.750101 | 0.51 | 32324 | 0.69885529 | CS |
| 12 | -0.1053 | -12.6062492518 | 0.8353 | 1.12 | 0.51 | 76641 | 0.8919686 | CS |
| 26 | -0.46 | -38.6554621849 | 1.19 | 1.45 | 0.51 | 108565 | 1.05666921 | CS |
| 52 | -0.1002 | -12.0693808721 | 0.8302 | 1.45 | 0.51 | 146981 | 0.98246972 | CS |
| 156 | -9.41 | -92.8007889546 | 10.14 | 17.17 | 0.0675 | 2030857 | 0.51449757 | CS |
| 260 | -9.41 | -92.8007889546 | 10.14 | 17.17 | 0.0675 | 2030857 | 0.51449757 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.